Will writes: Dr. Griffin, I realize you have addressed nearly every variation on the theme of “should this patient get Evusheld?” but my father in law is 83 years old and had a splenectomy 8…
In his weekly clinical update Dr. Griffin discusses the public health response to a polio case in a unvaccinated NY state resident, human to dog transmission of monkeypox virus, Tecovirimat and the treatment of monkeypox, detection of asymptomatic monkeypox virus infections among male sexual health clinic attendees in Belgium, what to do if you are exposed to SARS-CoV-2 and isolation and precautions for people with COVID-19, risk of SARS-CoV-2 infection in health care workers, effectiveness of HEPA filters at removing infectious SARS-CoV-2 from the air, Pfizer reports additional data on Paxlovid, hospitalization encounters for infection after Paxlovid, a randomized trial of Metformin, Ivermectin, and Fluvoxamine, and readmissions, post-discharge mortality and sustained recovery among patients admitted to hospital with COVID-19.
Bob writes: Dear Twivers. Just to break with the usual, I will start with the “however” and close with platitudes (you can assume the best). I am writing from my office on an inpatient ward…
Karen writes: Is there any reason someone with eczema should not get the intradermal monkeypox vaccine? Thank you, Karen Beth writes: Dear Dr. Griffin, I am 57 years old and I was never immunized for…
Kayla writes: Hi Daniel, I’m a clinical pharmacist currently involved with COVID treatment through the VA. My role involves assessing patients for early outpatient treatment with either Paxlovid or molnupiravir. As you might expect I…
Chuck writes: My up-to-date vaccinated 65 year old spouse, who was symptomatic (very severe cough for three weeks) positive with Covid-19 on May 11, 2022 is a singer/musician/voice teacher. She completed a regimen of paxlovid….
In his weekly clinical update Dr. Griffin discusses monkeypox virus infection in humans across 16 countries, pregnancy outcomes after SARS-CoV-2 infection by trimester, vaccination intent and belief, antiviral drug treatment for non-severe disease, the association of smoking with infected hospitalized patients, the association of Paxlovid on negative conversion rates among high-risk patients with COVID-19, safety and efficacy of Molnupiravir, usage of enoxaparin for primary thromboprophylaxis, statin and aspirin as therapy in infected patients, post-COVID-19 conditions among children 90 days after SARS-CoV-2 Infection, and symptoms and risk factors for long COVID in non-hospitalized adults.
Kari writes: Hello Dr. Daniel Griffin, I am a 42 year old pregnant woman with no health conditions other than celiac disease, food allergies and mild asthma during wildfire season. I am due October 8…
Thomas writes: Hello Vincent, In the most recent episode with Paul Offit the question came up what long covid actually is. Both you and he suggested that if fatigue was a criterion that you both…
TWiV reviews the FDA decision to update COVID-19 vaccine boosters in the fall, the meaning of fatigue with respect to long COVID, and a skin volatile induced by flavivirus reproduction that attracts mosquitoes to the infected host.
The Hosts of TWiV
Vincent Racaniello, Ph.D.
Brianne Barker, Ph.D.
Rich Condit, Ph.D.
Alan Dove, Ph.D.
Daniel Griffin, M.D.,
Ph.D., CTropMed CTH
Angela Mingarelli, DVM
Jolene Ramsey, Ph.D.
Kathy Spindler, Ph.D.